UPDATE: Piper Jaffray Raises Price Target on AtriCure to $14

According to Piper Jaffray, AtriCure

price target is raised to $14. Piper Jaffray said that AtriCure has been shackled by its lack of ability to market the company's key atrial fibrillation (

) products for that indication. “We are upgrading to Overweight from Neutral and raising our PT to $14 from $11 based on improving earnings potential.” AtriCure closed yesterday at $10.35.